Alterations in immune cell phenotype and cytotoxic capacity in HER2+ breast cancer patients receiving HER2-targeted neo-adjuvant therapy

BACKGROUND: The phase II neo-adjuvant clinical trial ICORG10-05 (NCT01485926) compared chemotherapy in combination with trastuzumab, lapatinib or both in patients with HER2+ breast cancer. We studied circulating immune cells looking for alterations in phenotype, genotype and cytotoxic capacity (dire...

Descripción completa

Detalles Bibliográficos
Autores principales: Gaynor, Nicola, Blanco, Alfonso, Madden, Stephen F., Moran, Barry, Fletcher, Jean M., Kaukonen, Damien, Ramírez, Javier Sánchez, Eustace, Alex J., McDermott, Martina S. J., Canonici, Alexandra, Toomey, Sinead, Teiserskiene, Ausra, Hennessy, Bryan T., O’Donovan, Norma, Crown, John, Collins, Denis M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10491671/
https://www.ncbi.nlm.nih.gov/pubmed/37507543
http://dx.doi.org/10.1038/s41416-023-02375-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10491671/
https://www.ncbi.nlm.nih.gov/pubmed/37507543
http://dx.doi.org/10.1038/s41416-023-02375-y

Ejemplares similares